Our Blogs

Safer Pain Management: Pharmacogenomics and Codeine

Codeine, typically used for mild to moderate pain, as well as cough suppression, is the most commonly prescribed opioid. However, its effectiveness can be variable depending on the individual being treated. Additionally, there are concerns about its role in addiction and the possibility of severe adverse reactions.

This prompts a need to investigate genetic factors that play a role in its metabolism. Pharmacogenomics, the study of how genes influence drug response, offers crucial insight into why codeine works well for some patients and poses significant risks for others.

Codeine Metabolism and the Role of CYP2D6

The liver’s CYP2D6 enzyme metabolizes about 25% of all prescription drugs. Codeine is one of these drugs, and its effectiveness relies on the CYP2D6 enzyme’s ability to convert codeine to its active form, morphine. Morphine provides the primary pain-relieving effects, and codeine itself functions more like a prodrug, requiring adequate enzymatic conversion to deliver a therapeutic benefit.

CYP2D6 Phenotypes and Clinical Implications

The activity of CYP2D6 varies widely due to genetic polymorphisms. Individuals can be categorized into four different metabolizer types based on their CYP2D6 variants:

1. Poor metabolizers (PM): Carry two nonfunctional alleles (e.g., *5/*5). These individuals produce minimal morphine, resulting in inadequate or no pain relief. It’s advised to choose an alternative drug for pain relief.
2. Intermediate metabolizers (IM): Carry one reduced-function and one nonfunctional allele. They have reduced morphine conversion and often experience subtherapeutic analgesia. It’s recommended to be aware of possible reduced effectiveness and try a dose increase if needed, or a non-tramadol opioid.
3. Extensive (normal) metabolizers (EM): Typically carry functional alleles such as *1 or *2 and generally metabolize codeine effectively, experiencing expected pain relief. It’s recommended to take codeine as indicated on the label.
4. Ultrarapid metabolizers (UM): Carry multiple functional alleles (e.g., *1/*2xN), leading to rapid conversion of codeine into morphine, increasing the risk of toxicity and potentially leading to overdose symptoms with normal doses. It’s recommended to select an alternative to codeine when possible.

These variations significantly impact both the efficacy and safety of codeine. For example, a *1/*2xN genotype may result in morphine levels up to 2 times higher than those seen in normal metabolizers. This would increase the risk of adverse drug reactions (ADRs), including life-threatening respiratory depression. Conversely, individuals with a *5/*5 genotype derive little to no pain relief, which could potentially lead to continued dose increases and therefore risk of opioid misuse.

*A note on allele notations described above: These represent different versions (alleles) of the CYP2D6 gene inherited from each parent.

1. *1: A normal-function allele.
2. 
   
3. *2: Also a normal-function allele.
4. 
   
5. *5: A no-function allele, typically representing a gene deletion (the gene is missing or inactive).
6. 
   
7. xN: Indicates gene duplication or multiplication. For example, *2xN means multiple copies (more than two) of the *2 allele, which can lead to increased enzyme activity.

Clinical Guidelines for Safer Prescribing

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has developed evidence-based guidelines for codeine prescribing based on one’s CYP2D6 genotype. These guidelines recommend avoiding codeine in both ultrarapid and poor metabolizers due to increased risk of toxicity and lack of efficacy, respectively. For these patients, alternative pain relief drugs that aren’t influenced by CYP2D6 activity are recommended. This could be morphine (the directly active form) or non-opioid options such as acetaminophen or NSAIDs.

Practical Recommendations for Healthcare Providers

1. Incorporate pharmacogenetic testing for CYP2D6 when considering codeine, particularly in populations with variable or unknown metabolizer status.
2. Use electronic health records and clinical support tools to help guide medication choices based on a patient's genetic test results.
3. Educate patients on the rationale for medication choices based on genetic information, emphasizing safety and personalized care.
4. Consider alternative pain management strategies based on the patient’s CYP2D6 phenotype.

Summary

Codeine’s safety and effectiveness can vary greatly depending on a patient’s CYP2D6 genotype. Poor metabolizers may get little relief, while ultrarapid metabolizers face serious toxicity risks. As precision medicine becomes more integrated into routine care, pharmacogenomics provides an essential tool to guide treatment decisions. By using CYP2D6 testing, clinicians can more safely and effectively manage pain, reduce the risk of opioid-related harm, and tailor care to each individual.

To optimize your approach to pain management, consider integrating CYP2D6 pharmacogenomic testing into clinical practice. Scylex offers targeted solutions to support personalized medicine, helping you make safer, more effective prescribing decisions for your patients.

Written By:

Vanessa Imus, MS, RDN,

Owner of Integrated Nutrition for Weight Loss

https://inutritioncenter.com/about/